



**Office of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda**

January 16, 2007 6:30 – 9:00 p.m. **PLEASE NOTE DATE**

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Nominations and Election of Chair** **7:00 - 7:05**

- 3. Approval of DUR Board Minutes** **7:05 - 7:10**
(Public Comment Prior to Board Action)

- 4. OVHA Pharmacy Administration Updates** **7:10 - 7:15**
 - Findings of the Vermont Auditor of Accounts

- 5. Medical Director Update** **7:15 - 7:25**
 - Clinical Programs Update
 - Prescriber Comments

- 6. Follow-up Items from Previous Meeting** **7:25 - 7:30**
 - Anti-infectives: Topical

- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **7:30 - 7:40**
(Public comment prior to Board action)
 - Antihypertensives: ARBs & ARB Combinations
 - Lipotropics
 - Pulmonary: Leukotriene Modifiers

- 8. Clinical Update: New Drug Reviews** **7:40 – 7:50**
(Public comment prior to Board action)
 - Daytrana[®] Patch (methylphenidate)

- 9. Drug Classes – New** **7:50 – 8:35**
 - Smoking Cessation: Nicotine Replacement/Oral
 - ❖ Chantix[®] (varenicline) – New Drug Review
 - Constipation: Chronic
 - ❖ Amitiza[®] (lubiprostone) – New Drug Review
 - ❖ Zelnorm[®] (tegaserod) – Abbreviated New Drug Review
 - Chemical Dependency Treatments
 - ❖ Vivitrol[®] Injection (naltrexone) – New Drug Review
 - ❖ Methadone – FDA Alert
 - Lipotropics: Bile Acid Sequestrants
 - Anti-infectives: Penicillins
 - Psoriasis: Non-biological, Oral
 - Psoriasis: Non-biological, Topical

- | | |
|---|--------------------|
| 10. RetroDUR | 8:35 - 8:50 |
| <ul style="list-style-type: none">▪ Final analysis regarding beneficiaries with extensive use of short-acting beta-agonist with no controller medication and long-acting beta-agonist use with no controller medication▪ November - Duplicate Therapy with Atypical Antipsychotics▪ January – Long Acting Narcotics | |
| 11. Updated New-to-Market Drug Monitoring Log | 8:50 - 8:55 |
| 12. General Announcements | 8:55 - 9:00 |
| 13. Adjourn | 9:00 |